Can-Fite BioPharma Ltd. saw a significant price increase of 15.10%, crossing above its 5-day SMA, amid a generally weak market with the Nasdaq-100 down 0.10% and the S&P 500 down 0.06%.
This surge is attributed to Can-Fite's recent announcement of securing a patent in Brazil for its A3 adenosine receptor agonists used in treating sexual dysfunction, which strengthens its global patent portfolio and opens up strategic opportunities in the Latin American market. The patent grant reflects the company's commitment to expanding its therapeutic offerings and could lead to future commercialization opportunities.
The implications of this patent grant are substantial, as it not only enhances Can-Fite's competitive edge in the growing sexual health market but also positions the company favorably for potential partnerships and increased investor interest, despite the overall market's downward trend.
Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.100
Low
2.50
Averages
2.50
High
2.50
Current: 4.100
Low
2.50
Averages
2.50
High
2.50
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
2025-12-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2025-12-24
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma to Hold from Buy with no price target after the company's board approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio. The firm is lowering its rating ahead of the actual split, consistent with its policy, the analyst noted.
H.C. Wainwright
H.C. Wainwright
initiated
$2.50
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$2.50
2025-11-04
initiated
Reason
H.C. Wainwright assumed coverage of Can-Fite BioPharma with a Buy rating and $2.50 price target. The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CANF
Unlock Now
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-15
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-04-15
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-03-21
Maintains
Strong Buy
Reason
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
